Pharmazym
ActiveFinancials · financial year 2025, full format
Annual accounts 2025 filed on 15-07-2026 at the NBB all 2 filings
Every figure per financial year
The operating result for 2025 is a loss of €32,625, smaller than the loss of €57,678 in 2024.
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Other operating charges640/8 | - | €47 | - |
| Gross operating margin9900 | -€57,678 | -€32,577 | ▲ 43.5% |
| Operating profit (loss)9901 | -€57,678 | -€32,625 | ▲ 43.4% |
| Financial charges65/66B | €124 | €413 | ▲ 232% |
| Recurring financial charges65 | €124 | €413 | ▲ 232% |
| Profit (loss) for the period before taxes9903 | -€57,803 | -€33,037 | ▲ 42.8% |
| Income taxes67/77 | €13,812 | - | - |
| Profit (loss) for the period9904 | -€71,615 | -€33,037 | ▲ 53.9% |
| Profit (loss) for the period to be appropriated9905 | -€71,615 | -€33,037 | ▲ 53.9% |
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Assets | |||
| Total assets20/58 | €246,411 | €212,870 | ▼ 13.6% |
| Current assets29/58 | €246,411 | €212,870 | ▼ 13.6% |
| Amounts receivable within one year40/41 | €132,327 | €161,971 | ▲ 22.4% |
| Other amounts receivable41 | €132,327 | €161,971 | ▲ 22.4% |
| Cash at bank and in hand54/58 | €114,083 | €50,898 | ▼ 55.4% |
| Equity and liabilities | |||
| Total equity and liabilities10/49 | €246,411 | €212,870 | ▼ 13.6% |
| Equity10/15 | €243,385 | €210,348 | ▼ 13.6% |
| Contributions10/11 | €315,000 | €315,000 | = |
| Capital10 | €315,000 | €315,000 | = |
| Issued capital100 | €315,000 | €315,000 | = |
| Profit (loss) carried forward14 | -€71,615 | -€104,652 | ▼ 46.1% |
| Amounts payable17/49 | €3,026 | €2,522 | ▼ 16.6% |
| Amounts payable within one year42/48 | €3,026 | €2,522 | ▼ 16.6% |
| Trade debts44 | €3,026 | €2,522 | ▼ 16.6% |
| Suppliers440/4 | €3,026 | €2,522 | ▼ 16.6% |
| Line | 2024 | 2025 | Change |
|---|---|---|---|
| Profit (loss) for the period9904 | -€71,615 | -€33,037 | ▲ 53.9% |
| Operating cash flow (approximation) | -€71,615 | -€33,037 | ▲ 53.9% |
| Change in cash | - | -€63,185 | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Historical observation
In July 2024, 3,223 companies had the same profile as Pharmazym has now. Two years later, 87.7% were still going and 3.4% had gone bankrupt.
- Micro
- 2 to 5 years old
- solvency 30% or more
- a loss of 10% of the balance sheet or more
Another 0.2% stopped without a precise date, possibly only after those two years.
The bankruptcy probability of Pharmazym itself is lower: 0.3% within 12 months. It rests on far more data about Pharmazym than the profile alone.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 3,223 companies, not a prediction for Pharmazym. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.